PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
V Ramakrishnan, S Kumar - Leukemia & lymphoma, 2018 - Taylor & Francis
Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second
most common hematological malignancy. The disease is characterized by the accumulation …
most common hematological malignancy. The disease is characterized by the accumulation …
New insights in anti-angiogenesis in multiple myeloma
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and involves
direct production of angiogenic cytokines by plasma cells and their induction within the bone …
direct production of angiogenic cytokines by plasma cells and their induction within the bone …
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
J Hu, WX Hu - Cancer letters, 2018 - Elsevier
Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia,
hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic …
hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic …
[PDF][PDF] Drug targets and resistance mechanisms in multiple myeloma
J Nass, T Efferth - Cancer Drug Resist, 2018 - pdfs.semanticscholar.org
Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood
cancer (10%). A PubMed search has been conducted for English research papers and …
cancer (10%). A PubMed search has been conducted for English research papers and …
[PDF][PDF] Investigating MEK inhibition in the treatment of multiple myeloma
JAYJ HOCKING - 2018 - scholar.archive.org
Multiple myeloma is an incurable haematologic malignancy. Therapeutic advances continue
to improve overall survival, but there remains a need for the ongoing development of novel …
to improve overall survival, but there remains a need for the ongoing development of novel …